New York, NY, United States

Time filter

Source Type

Patent
Intercept Pharmaceuticals and Dainippon Sumitomo | Date: 2016-04-26

The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.


Patent
Intercept Pharmaceuticals | Date: 2017-04-05

The invention relates to compounds of Formula (A): (A) or a salt, solvate, hydrate, or amino acid conjugate thereof. The compounds of formula A are TGR5 modulators useful for the prevention and treatment of disease.


Patent
Intercept Pharmaceuticals | Date: 2016-10-07

The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R^(1)-R^(10), m, n, p, and


Patent
Intercept Pharmaceuticals | Date: 2017-06-07

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the famesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.


Patent
Intercept Pharmaceuticals | Date: 2016-10-21

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.


Patent
Intercept Pharmaceuticals | Date: 2016-01-28

The present invention relates to methods of treating, reducing the risk of, preventing, or alleviating a symptom of a pulmonary disease or condition, reducing or suppressing inflammation in the lung, and promoting lung repair, by using a compound of formula A: or a pharmaceutically acceptable salt thereof.


Patent
Intercept Pharmaceuticals | Date: 2015-11-20

The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.


Patent
Intercept Pharmaceuticals | Date: 2016-02-05

The invention relates to compounds of formula (I):


The present invention relates to compounds of formula (I):


Patent
Intercept Pharmaceuticals | Date: 2015-11-20

The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

Loading Intercept Pharmaceuticals collaborators
Loading Intercept Pharmaceuticals collaborators